# RECEIVED CENTRAL FAX CENTER

Ø001/027

OFFICIAL

AUG 1 7 2004

·						PTO/SB/21 (02-04) gh 07/31/2006, OMB 0651-0031 PEPARTMENT OF COMMERCE
Under the Pagenwork Reduction Act of 1995	RO DEMON	Application Number	10/005.	<u>സവ്ശാചനടെ</u>	it disnit	ove a valid OMB control number.
TRANSMITTAL FORM  (to be used for all correspondence after initial filing)		Filing Date	12/7/20			
		First Named Inventor	Peter W. BRINGMANN 1647 Christine J. SACUD			
		Art Unit				
		Examiner Name				
T-		Allomey Docket Number	<del>-  </del>			
Total Number of Pages in This Submission	57	- morroy occurrent to	51835A	USM1		
	ENCI	OSURES (Check all the	et apply)			
Fee Transmittal Form  Feo Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Response to Missing Parts/ Incomplate Application  Response to Missing Parts  under 37 CFR 1.52 or 1.53	Remar	Drawing(s)  Licensing-related Papers  Petition  Potition to Convert to a  Provisional Application  Power of Attorney, Revocation  Change of Correspondence Add  Ferminal Disclaimer  Request for Refund  CD, Number of CD(s)  Exament is being faxed to Centra		to To To App of A Asp (App Prop State Associate	echnok cal Cor ppeals eal Cor eal Not prietary us Lett er End tify bel	osure(s) (please low); of Attorney
SIGNA	TURE O	F APPLICANT, ATTORN	łEY, OI	R AGENT		
Firm Anna Gil, Registration No. Individual name	. 48,726					
Signature	· 【		<del></del>			
Date August 17, 2004			_			
C	ERTIFIC	ATE OF TRANSMISSIO	N/M A P	ING		
I hereby certify that this correspondence is b sufficient postage as first class mail in an entitle date shown below.	eino facsi	nile transmitted to the USPTO o	v danneit	ed with the I	Jnited :	States Postal Service with andria, VA 22313-1450 on
Typed or printed name Anna Gil		,			-	
Signature (	<i>∴</i>				Date	August 17, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the including case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re to the Application of:

Peter W. BRINGMANN et al.

Examiner:

Christine J. Saoud

Serial No.: 10/005,646

Group Art Unit: 1647

Filed:

7 December 2001

Title:

NOVEL FIBROBLAST **GROWTH FACTORS** 

Docket No.: 51835AUSM1

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### **RESPONSE TO OFFICE ACTION**

#### Dear Sir:

This communication is responsive to the Office Action mailed 17 March 2004, in the above-referenced application. Applicants respectfully request consideration of the following remarks and amendments responsive to this Office Action.

A request for a two-month extension for responding to this Office Action is enclosed herewith, making the due date for responding to the Office Action, 17 August 2004.

The Commissioner is hereby authorized to charge any fees associated with this response, or credit any overpayment, to Deposit Account No. 02-2117.

## **AMENDMENTS**

#### In the Claims:

Please cancel Claims 1-35, 42-68, and 70, because the claims have been withdrawn from consideration under 37 CFR 1.142(b), as allegedly being drawn to a non-elected invention. A clean copy of the pending claims as amended are attached herewith in the Appendix.

Please amend Claims 36, 39, 40, and 41 as follows:

- 36. (Once Amended) A method to treat spinal cord damage; spinal cord trauma; neuronal tissue damage produced by [Ischemic attach, infarction, hemorrhage or aneurysm; Huntingtons' disease;] multiple sclerosis[; myelopathy; myelitis; or syringomyelia], comprising administering to a patient in need thereof an effective amount of an FGF-9 polypeptide or a biologically active fragment thereof.
- 39. (Once Amended) The method of Claim 36, wherein said polypeptide comprises amino acid 1 to amino acid 208 as set forth in Fig. 3 (SEQ ID NO: 5).